Scientists have been trying for more than 40 years to develop anHIV vaccine.
To date, only six vaccine candidates have progressed to large-scale human testing.
What Are Mosaic Vaccines?
FatCamera / Getty Images
Mosaic vaccines differ from previous vaccine models in that they are not constrained to only predominant variants of HIV.
Instead, mosaic vaccines take pieces of different HIV viruses and combine them to trigger a broader immune response.
Based on the positive findings, a Phase 3 trial called MOSAICO was launched in 2019.
Results are expected in 2024.
Even more promising were the results seen in the parallel animal study.
Despite the repeated exposures, 66% of vaccinated monkeys remained SIV-free.
For this reason, the MOSAICO trial is crucial.
Even so, there are other HIV vaccine models receiving equal attention.
It was hoped that injecting the lab-made version into a persons body might trigger the same protective response.
Even so, the vaccine was not able to stop HIV infection.
If any or all of the vaccines are shown to be safe and able to generate an HIV-specific response.
the HVTN 302 study will be expanded to investigate how effective the vaccine candidates are.
The results of the Phase 1 trial are expected by late 2023.
When the inactivated vaccine is injected into the body, it stimulates a broader immune response.
Mosaic vaccines are just one of several HIV vaccine models under investigation.
National Institute of Allergies and Infectious Diseases.History of HIV vaccine research.
HIV Preventive Trials connection.Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains.
U.S. Centers for Disease Control and Prevention.Understanding mRNA COVID-19 vaccines.
Bloomberg School of Public Health.
John Hopkins University.The long history of mRNA vaccines.
National Institutes of Health.NIH launches clinical trial of three mRNA HIV vaccines.
Centers for Disease Control and Prevention.Preventing HIV with PrEP.
Food and Drug Administration.FDA approves first injectable treatment for HIV pre-exposure prevention.
